Bloomberg Talks
Moderna CEO Talks Company Earnings
May 2, 2024
Modern CEO Stephane Bancel discusses company earnings and cost-cutting benefits in response to Covid business decline. Topics include balancing cost efficiency with innovation, progress on a melanoma vaccine, potential accelerated approval, and the impact of AI on drug production and clinical development.
08:12
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Moderna focuses on cost-cutting and innovation to drive sales and research.
- Artificial intelligence accelerates drug discovery and process optimization at Moderna.
Deep dives
Moderna's Cost-Cutting Strategy and R&D Focus
Moderna CEO Stefan Bansell discusses the balance between cost-cutting and innovation, highlighting the company's emphasis on driving sales and research. The company has strategically prioritized investments, such as in respiratory vaccines, where phase three studies help reduce costs. Additionally, partnerships like the one with Merck allow for shared expenses, enhancing efficiency in research and development. Bansell emphasizes the importance of technology, including AI, in scaling the company and increasing productivity across various areas like manufacturing and commercial operations.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
